Comparative Pharmacology
Head-to-head clinical analysis: NERLYNX versus STIVARGA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NERLYNX versus STIVARGA.
NERLYNX vs STIVARGA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neratinib is an irreversible pan-ErbB receptor tyrosine kinase inhibitor that inhibits EGFR, HER2, and HER4, leading to reduced downstream signaling and cell proliferation.
Multikinase inhibitor that inhibits VEGFR-1, -2, -3, PDGFR-α, PDGFR-β, FGFR-1, -2, TIE2, KIT, RET, RAF-1, and B-RAF.
NERLYNX (neratinib) 240 mg (6 tablets of 40 mg) orally once daily with food for a total duration of 1 year.
160 mg orally once daily for 3 weeks, followed by 1 week off (28-day cycle).
None Documented
None Documented
Terminal half-life approximately 7–17 days (mean ~9 days) after a 240 mg daily dose, supporting once-daily dosing. Steady state reached by ~4–6 weeks.
Terminal elimination half-life is approximately 30 hours (range 15-42 h) for regorafenib and 25-60 h for its active metabolites M-2 and M-5. Steady-state is reached within 2-3 weeks.
Primarily hepatic metabolism; 97% of dose recovered in feces (including unchanged drug and metabolites), <1% in urine as unchanged drug. Biliary excretion is a major route.
Approximately 51% fecal (as unchanged drug and metabolites), 19% renal (as metabolites, <1% unchanged).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor